Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,
https://www.pharmalive.com/wp-content/uploads/2021/11/U.S.-FDA-extends-review-of-Bristol-Myers-heart-disease-drug-Reuters-11-19-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-15 17:15:232022-09-16 10:50:11Consumer group says drugmakers abuse U.S. patent system to keep prices high
